Kwang Dong Pharmaceutical Co., Ltd. (009290) Price & Analysis

― Followers

009290 Stock Chart & Stats

₩6360.00

-₩90.00(-1.40%)

Oct 27, 2026

―

Day’s Range― - ―

52-Week Range₩5,150.00 - ₩12,800.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)132.60K

Market Cap

₩299.17B

Enterprise Value₩473.63B

Total Cash (Recent Filing)₩177.70B

Total Debt (Recent Filing)₩300.93B

Price to Earnings (P/E)12.6

Beta0.18

Next Earnings

Nov 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.57%

Share Statistics

EPS (TTM)504.90

Shares Outstanding49,799,810

10 Day Avg. Volume149,933

30 Day Avg. Volume132,599

Financial Highlights & Ratios

PEG Ratio-0.23

Price to Book (P/B)0.47

Price to Sales (P/S)0.19

P/FCF Ratio5.38

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Accelerating Revenue GrowthFaster TTM revenue growth indicates stronger recent demand across the company’s pharmaceutical and health-product portfolio. If sustained, this broader sales base can improve operating leverage, support channel strength, and provide a foundation for rebuilding profitability over the next several quarters.

Manageable LeverageModerate leverage and a substantial equity base provide Kwang Dong with financial flexibility relative to a more heavily indebted business. This balance-sheet position can help preserve funding capacity for operations and growth while reducing pressure from debt servicing during periods of weaker profitability.

Positive TTM Free Cash FlowPositive TTM free cash flow shows that the business still generated cash after investment needs, despite weaker performance than the prior year. That provides some internal funding for operations and capital allocation, although the declining level means this support should be viewed as conditional rather than fully durable.

Bears Say

Thin And Recently Negative MarginsVery thin net margins leave limited earnings protection if costs rise or sales growth moderates. The shift to negative TTM operating and EBITDA margins is more concerning because it signals pressure in the core business, potentially limiting reinvestment, weakening resilience, and reducing the benefit of higher revenue.

Volatile Cash GenerationRepeated swings in operating cash flow make reported earnings less dependable as a source of funding. The sharp TTM decline and modest cash conversion suggest working-capital or operating volatility, which could constrain internally funded investment and make future cash generation less predictable.

Weak Capital EfficiencyFalling returns on equity indicate that Kwang Dong is currently converting its capital base into profits less efficiently than in earlier periods. Persistently low returns can limit earnings quality, reduce the economic payoff from reinvestment, and make stronger revenue growth less valuable unless margins recover.

009290 FAQ

What was Kwang Dong Pharmaceutical Co., Ltd.’s price range in the past 12 months?

Kwang Dong Pharmaceutical Co., Ltd. lowest stock price was ₩5150.00 and its highest was ₩12800.00 in the past 12 months.

What is Kwang Dong Pharmaceutical Co., Ltd.’s market cap?

Kwang Dong Pharmaceutical Co., Ltd.’s market cap is ₩299.17B.

When is Kwang Dong Pharmaceutical Co., Ltd.’s upcoming earnings report date?

Kwang Dong Pharmaceutical Co., Ltd.’s upcoming earnings report date is Nov 12, 2026 which is in 15 days.

How were Kwang Dong Pharmaceutical Co., Ltd.’s earnings last quarter?

Kwang Dong Pharmaceutical Co., Ltd. released its earnings results on Aug 12, 2026. The company reported ₩54.485 earnings per share for the quarter.

Is Kwang Dong Pharmaceutical Co., Ltd. overvalued?

According to Wall Street analysts Kwang Dong Pharmaceutical Co., Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kwang Dong Pharmaceutical Co., Ltd. pay dividends?

Kwang Dong Pharmaceutical Co., Ltd. pays a Annually dividend of ₩100 which represents an annual dividend yield of 1.57%. See more information on Kwang Dong Pharmaceutical Co., Ltd. dividends here

What is Kwang Dong Pharmaceutical Co., Ltd.’s EPS estimate?

Kwang Dong Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kwang Dong Pharmaceutical Co., Ltd. have?

Kwang Dong Pharmaceutical Co., Ltd. has 49,799,810 shares outstanding.

What happened to Kwang Dong Pharmaceutical Co., Ltd.’s price movement after its last earnings report?

Kwang Dong Pharmaceutical Co., Ltd. reported an EPS of ₩54.485 in its last earnings report. Following the earnings report the stock price went down -0.744%.

Which hedge fund is a major shareholder of Kwang Dong Pharmaceutical Co., Ltd.?

Currently, no hedge funds are holding shares in KR:009290

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kwang Dong Pharmaceutical Co., Ltd.

Established in Seoul, South Korea, in 1963, Kwang Dong Pharmaceutical Co., Ltd. functions as a diversified healthcare enterprise. The company is actively involved in the development and distribution of an extensive range of pharmaceutical products. This portfolio includes various over-the-counter (OTC) remedies addressing common ailments such as coughs and colds, eye care, liver conditions, mineral deficiencies, vitamin supplementation, circulatory health, and general wellness tonics. Complementing these are its prescription-only (ETC) medicines, which encompass treatments for a broad spectrum of medical needs, including diabetes, cardiovascular disorders, metabolic imbalances, digestive issues, immune system modulation, obesity, genitourinary and anal conditions, neurological and psychiatric disorders, pain and inflammation, infections, and anti-cancer therapies. Beyond pharmaceuticals, Kwang Dong offers health supplements and a diverse selection of beverages, ranging from general consumer drinks to functional and traditional health-focused options. The company also extends its operations to include the management of hospitals and facilitates widespread product distribution through various retail and wholesale channels, including discount stores, television home shopping, and online e-commerce platforms. Furthermore, Kwang Dong Pharmaceutical acts as a comprehensive MRO (Maintenance, Repair, and Operations) service provider, specializing in the procurement of raw materials, intermediate goods, and industrial consumables, with services extending to construction and international sourcing.